<VariationArchive RecordType="classified" VariationID="649625" VariationName="NC_000011.10:g.(?_108267161)_(108365518_?)del" VariationType="Deletion" Accession="VCV000649625" Version="2" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-10-15" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="652036" VariationID="649625">
      <GeneList>
        <Gene Symbol="ATM" FullName="ATM serine/threonine kinase" GeneID="472" HGNC_ID="HGNC:795" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108223067" stop="108369102" display_start="108223067" display_stop="108369102" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108093558" stop="108239825" display_start="108093558" display_stop="108239825" Strand="+" />
          </Location>
          <OMIM>607585</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=ATM">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="C11orf65" FullName="chromosome 11 open reading frame 65" GeneID="160140" HGNC_ID="HGNC:28519" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108308519" stop="108469881" display_start="108308519" display_stop="108469881" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="108253726" stop="108338257" display_start="108253726" display_stop="108338257" Strand="-" />
          </Location>
        </Gene>
        <Gene Symbol="LOC128772356" FullName="melanoma risk locus-associated MPRA allelic enhancer 11:108140516" GeneID="128772356" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108269717" stop="108269861" display_start="108269717" display_stop="108269861" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC129390354" FullName="MPRA-validated peak1451 silencer" GeneID="129390354" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>11q22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="108338929" stop="108339129" display_start="108338929" display_stop="108339129" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NC_000011.10:g.(?_108267161)_(108365518_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11q22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" innerStart="108267161" innerStop="108365518" display_start="108267161" display_stop="108365518" variantLength="98358" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" innerStart="108137888" innerStop="108236245" display_start="108137888" display_stop="108236245" variantLength="98358" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.(?_108267161)_(108365518_?)del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.(?_108267161)_(108365518_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.(?_108137888)_(108236245_?)del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.(?_108137888)_(108236245_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000011.10:g.(?_108267161)_(108365518_?)del AND Ataxia-telangiectasia syndrome" Accession="RCV000804604" Version="2">
        <ClassifiedConditionList TraitSetID="770">
          <ClassifiedCondition DB="MedGen" ID="C0004135">Ataxia-telangiectasia syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-01-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-01-03" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-09" MostRecentSubmission="2020-04-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19781682</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23532176</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23807571</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25460276</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25614872</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9443866</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="770" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4635" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ataxia-telangiectasia syndrome</ElementValue>
                <XRef ID="Ataxia+Telangiectasia/637" DB="Genetic Alliance" />
                <XRef ID="68504005" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">AT, COMPLEMENTATION GROUP C</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, COMPLEMENTATION GROUP A</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0001" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ATAXIA-TELANGIECTASIA, FRESNO VARIANT</ElementValue>
                <XRef Type="Allelic variant" ID="607585.0014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group E</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ataxia-telangiectasia, complementation group D</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Louis-Bar syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebello-oculocutaneous telangiectasia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with ataxia telangiectasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AT1</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATC</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATA</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATD</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">AT</ElementValue>
                <XRef Type="MIM" ID="208900" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">A-T</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATM</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">ATE</ElementValue>
                <XRef ID="208900" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5862" />
                <XRef ID="5862" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia.</Attribute>
                <XRef ID="NBK26468" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301790</ID>
                <ID Source="BookShelf">NBK26468</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301317</ID>
                <ID Source="BookShelf">NBK1138</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS, 2010">
                <ID Source="PubMed">20050888</ID>
              </Citation>
              <Citation Type="general" Abbrev="EFNS/ENS, 2014">
                <ID Source="PubMed">24418350</ID>
              </Citation>
              <XRef ID="100" DB="Orphanet" />
              <XRef ID="C0004135" DB="MedGen" />
              <XRef ID="MONDO:0008840" DB="MONDO" />
              <XRef Type="MIM" ID="208900" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1838519" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-09" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="5670010|MedGen:C0004135" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000944521" DateUpdated="2020-04-09" DateCreated="2019-08-14" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23532176</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9443866</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25614872</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23807571</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19781682</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25460276</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 17-63 of the ATM gene. The 5' boundary is likely confined to intron 16. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. Deletion of exons 17-63 has not been reported in the literature in individuals with ATM-related disease. This gross deletion eliminates the last 2,234 amino acid residues of the ATM protein, including the FAT, PI3/4 kinase, and FATC or PIK-related kinase domains, which are crucial for the proper function of the ATM protein (PMID: 23532176, 25460276, 19781682). In addition, several downstream gross deletions encompassing exons 38-63, exons 46-63, exons 57-63 and exons 62-63 of ATM have been reported in individuals with ataxia-telangiectasia, and determined to be pathogenic (PMID: 25614872, 23807571, 9443866, 25614872). This suggests that deletion of this region of the ATM protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ATM" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.(?_108137888)_(108236245_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Ataxia-telangiectasia syndrome</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0004135" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1838519" TraitType="Disease" MappingType="Name" MappingValue="Ataxia-telangiectasia syndrome" MappingRef="Preferred">
        <MedGen CUI="C0004135" Name="Ataxia-telangiectasia syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

